Biocon
Ravi Mazumdar is the Non-Executive Director at Biocon. Ravi was previously the Vice President, Engineering at Flexera Software from December 2009 to October 2018. Ravi was responsible for the R&D and product delivery of the $45M Installation and Application Readiness product line of the company which includes award winning products, InstallShield, AdminStudio and InstallAnywhere. Managing a 50+ person strong globally distributed software development team.
Ravi worked within operating budget to re-org the team to support product growth which resulted in a 30% revenue growth (YOY 2009/2010). Prior to Flexera Software, they were the Vice President Engineering & Business Operations at TVCompass Inc from August 2006 to November 2009 where they established software engineering processes and enabled timely and high quality product releases for a handheld wireless universal remote control platform.
Ravi has a strong background in working with globally distributed software development teams and managing within an operating budget. Ravi has also closed deals with Target.com as well as other distribution partners.
Ravi Mazumdar received their MS in Industrial Engineering from The University of Texas at Arlington and their BS in Industrial and Production Engineering from Manipal Institute of Technology. Ravi also attended The Hyderabad Public School and Hyderabad Public School.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Biocon
21 followers
Biocon Limited is a biopharmaceutical company. The Company focuses to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through its products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. The Company has developed and taken a range of Novel Biologics, Biosimilars, differentiated Small Molecules and affordable Recombinant Human Insulin and Analogs from Lab to Market. The Company's brands include INSUGEN (rh-insulin), BASALOG (Glargine), CANMAb (Trastuzumab), BIOMAb-EGFR (Nimotuzumab) and ALZUMAb (Itolizumab), an anti-CD6 monoclonal antibody. It has a pipeline of Biosimilars and Novel Biologics at various stages of development, including Insulin Tregopil, an oral insulin analog.